Follow
Evan Warner
Evan Warner
PhD Student, University of British Columbia
Verified email at prostatecentre.com
Title
Cited by
Cited by
Year
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerctDNA and Resistance to AR-Targeted Therapy
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
3172018
Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
JAMA oncology 2 (12), 1598-1606, 2016
2912016
Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer
M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ...
European urology 72 (1), 34-42, 2017
1642017
Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer
G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ...
European urology 75 (4), 667-675, 2019
1102019
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyMolecular Analysis High-Risk …
H Beltran, AW Wyatt, EC Chedgy, A Donoghue, M Annala, EW Warner, ...
Clinical Cancer Research 23 (22), 6802-6811, 2017
642017
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerctDNA-Based Assessment of MMRd Prostate Cancer
E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ...
Clinical Cancer Research 26 (5), 1114-1125, 2020
432020
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8: 444–457. doi: 10.1158/2159-8290
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
CD-17-0937.[Abstract][CrossRef][Google Scholar], 0
41
Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer
C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ...
European urology 78 (6), 834-844, 2020
312020
DNA repair defects in prostate cancer: impact for screening, prognostication and treatment
EW Warner, SM Yip, KN Chi, AW Wyatt
BJU international 123 (5), 769-776, 2019
292019
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionBRCA2, ATM, and CDK12 in Prostate Cancer
E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ...
Clinical Cancer Research 27 (6), 1650-1662, 2021
232021
Moving toward personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-null neuroendocrine prostate cancer
ECP Chedgy, M Annala, K Beja, EW Warner, ME Gleave, KN Chi, ...
Clinical genitourinary cancer 14 (2), e233-e236, 2016
172016
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionProstate Cancer Evolution during Sequential AR Inhibition
M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ...
Clinical Cancer Research 27 (16), 4610-4623, 2021
132021
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8 (4): 444–457. doi: 10.1158/2159-8290
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
CD-17-0937.[Abstract][CrossRef][Google Scholar], 0
13
Tissue-and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review
K Van der Eecken, J Vanwelkenhuyzen, MP Deek, PT Tran, E Warner, ...
European Urology Oncology 4 (6), 914-923, 2021
102021
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016; 2: 1598–606
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
Clin Cancer Res 21, 2315-24, 2015
52015
Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.
S Yip, D Khalaf, WJ Struss, K Sunderland, G Vandekerkhove, EW Warner, ...
Journal of Clinical Oncology 36 (6_suppl), 242-242, 2018
42018
Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.
WJ Struss, M Annala, EW Warner, K Beja, G Vandekerkhove, A Wong, ...
Journal of Clinical Oncology 35 (6_suppl), 140-140, 2017
42017
Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations
E Warner, S Yip, M Annala, G Wang, A Angeles, A Beigi, E Schonlau, ...
CLINICAL CANCER RESEARCH 26 (11), 30-30, 2020
22020
Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients …
AW Wyatt, M Annala, K Beja, S Parimi, G Vandekerkhove, E Warner, ...
Annals of Oncology 27, vi17, 2016
22016
Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations
E Warner, S Yip, M Annala, G Wang, A Angeles, A Beigi, E Schönlau, ...
Clinical Cancer Research 26 (11_Supplement), PR09-PR09, 2020
12020
The system can't perform the operation now. Try again later.
Articles 1–20